Ask Me Anything – Updates to the Clozapine REMS Program

Feb 15th, 2019
Share
Share
Add To Calendar
Google Outlook Office365 Yahoo ICS

On February 28, 2019, a series of requirements will go into effect as a result of FDA’s modification to the Clozapine Risk Evaluation and Mitigation Strategy (REMS) Program. Of note, is a requirement for health care professionals prescribing clozapine, as well as pharmacies dispensing clozapine, to be certified in the clozapine REMS program. This session will discuss these new requirements and address participant questions.

This event is not designated for AMA PRA Category 1 CreditTM.

 

Register at SMIadviser.org/REMS

Feb 15th, 2019
non-image